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Epigenetic histone modifications play critical roles
in the control of gene transcription. Recently, an
increasing number of histone H2A deubiquitinases
have been identified and characterized. However,
the physiological functions for this entire group of
histone H2A deubiquitinases remain unknown. In
this study, we revealed that the histone H2A deubi-
quitinase MYSM1 plays an essential and intrinsic
role in early B cell development. MYSM1 deficiency
results in a block in early B cell commitment and
a defect of B cell progenitors in expression of EBF1
and other B lymphoid genes. We further demon-
strated that MYSM1 derepresses EBF1 transcription
in B cell progenitors by orchestrating histone modifi-
cations and transcription factor recruitment to the
EBF1 locus. Thus, this study not only uncovers the
essential role for MYSM1 in gene transcription during
early B cell development but also underscores the
biological significance of reversible epigenetic his-
tone H2A ubiquitination.
INTRODUCTION
Protein ubiquitination plays a critical role in a variety of cellular
processes, including protein degradation and trafficking, cell
cycle regulation, DNA repair, and transcriptional regulation
(Komander et al., 2009). Nucleosomes, the basic units of
chromatin, are composed of genomic DNA wrapped around
the core histone (H2A, H2B, H3, and H4) octamer. Histone
ubiquitination was discovered in 1975 and has since been
found to be a relatively abundant modification in eukaryotic
organisms (Goldknopf et al., 1975; Komander et al., 2009).
Histone H2A at the conserved residue lysine (K) 119 was found
to be monoubiquitinated (Komander et al., 2009). Poly-
ubiquitination of a protein is often marked for its degradation,
whereas monoubiquitination of histones usually represents
a nondegradative signal (Komander et al., 2009). Ring1B and
Bmi1, the core components of the polycomb repressive
complex 1 (PRC1), can ubiquitinate histone H2A (Cao et al.,
2005; de Napoles et al., 2004; Wang et al., 2004a, 2004b).IAnother H2A ubiquitinase, hRUL138, in the N-CoR and
HDAC1 corepressor complex was recently found to suppress
chemokine genes (Zhou et al., 2008). H2A ubiquitination is
generally associated with gene silencing and X chromosome
inactivation (Cao et al., 2005; de Napoles et al., 2004; Wang
et al., 2004a).
Recently, an increasing number of histone H2A deubiquiti-
nases, including ubiquitin-specific proteases (USP) 16 (Ubp-
M), USP21, USP22, MYSM1, and PR-DUB, have been identified
and characterized (Joo et al., 2007; Nakagawa et al., 2008;
Scheuermann et al., 2010; Zhao et al., 2008; Zhu et al., 2007).
USP16 plays a role in regulating the mitotic phase of the cell
cycle and homeobox gene expression (Cai et al., 1999; Joo
et al., 2007). USP22 is able to deubiquitinate histone H2A and
H2B in vitro and is required for androgen receptor transcription
activation (Zhao et al., 2008). Zhu et al. (2007) identified Myb-
like, SWIRM, and MPN domain-containing protein 1 (MYSM1)
as a histone H2A deubiquitinase (2A-DUB). The JAMM and
MPN metalloenzyme domain possesses an intrinsic metallopro-
tease activity that hydrolyzes the isopeptide bonds of ubiquitin
chains (Sato et al., 2008). The SANT (switching-defective protein
3, adaptor 2, nuclear receptor corepressor, and transcription
factor IIIB) domain is similar to the DNA-binding domain of
Myb-related proteins and is a motif that exists in many transcrip-
tion regulators and is capable of binding to DNA and histones
(Boyer et al., 2004). The SWIRM domain is named for its pres-
ence in the proteins Swi3, Rsc8, and Moira, which are members
of the SWI/SNF family of ATP-dependent chromatin-remodeling
complexes, and favors interactions with linker DNA and histone
H3 (Yoneyama et al., 2007). MYSM1 is required for the activa-
tion of several target genes in prostate cancer cells and is
a component of a complex that included the histone acetyl-
transferase PCAF (Zhu et al., 2007). Although the mechanisms
by which histone ubiquitinases regulate gene transcription are
unclear, it was proposed that MYSM1 forms a regulatory
complex to regulate transcription by a stepwise coordination
of histone acetylation, H2A deubiquitination, and linker histone
H1 disassociation from the nucleosome (Zhu et al., 2007).
Among various histone modifications, histone ubiquitination
remains the least understood despite its early discovery. In
particular, the physiological functions for this entire group of
histone H2A deubiquitinases remain unknown. The present
study revealed that the histone H2A deubiquitinase MYSM1 is
essential for early B cell development by derepressing EBF1
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Figure 1. MYSM1 Is Essential for B Cell Development
(A–D) Representative flow cytometry profiles of bone marrow (BM), spleen (SP), lymph node (LN), and peripheral blood (PB) from homozygousMysm1/ mice
and WT littermates (n = 8 per group, 6 weeks old) to identify total B cells (B220+CD19+) (A), percent cells expressing IgM and IgD (B) or immature B cells
(B220+IgM+) (C), and T cells (CD3+) (D). Numbers in quadrants indicate percent cells in each.
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MYSM1 Is Essential for B Cell Development
To investigate the physiological role of MYSM1, we generated
Mysm1 mRNA truncation-first floxed mice from the Mysm1-
targeted sperms in the C57BL/6J background provided by
the Knockout Mouse Project (KOMP) Repository (Figure S1A
available online). The Mysm1 mRNA truncation-first floxed
mice were characterized with genomic polymerase chain reac-
tion (PCR) and Southern blot analyses. To avoid potential tran-
scriptional leakage of the splice acceptor-capture and RNA
poly(A) termination strategy, Mysm1/ mice were generated
by crossing the Mysm1 mRNA truncation-first floxed mice
with MMTV-cre mice in the B6129F1 background to delete
the floxed Mysm1 exon (Figure S1A). MMTV-cre mice have
a widespread pattern of Cre expression in various cells
including B and T cells and their progenitors (Kasper et al.,
2006; Kim et al., 2008). Homozygous Mysm1/ mice were
fertile and viable, although they had truncated tails and growth
retardation (Figure S1B). Heterozygous mice did not differ in
morphology, growth, and viability from their wild-type (WT)
littermates. MYSM1 protein expression was drastically down-
regulated in the spleen and thymus as well as other tissues
of the Mysm1/ mice, as determined by immunoblot analysis
(Figure S1C). MYSM1 mRNA in sorted B cells, T cells, and
hematopoietic stem cells (HSCs) was reduced by more than
80% in the Mysm1/ mice, as detected by qRT-PCR
(Figure S1D).
We analyzed the effect of MYSM1 deficiency on the hemato-
poietic system by comparing the Mysm1/ mice with WT
littermates. Several tissues and organs of 6-week-old mice
were analyzed by flow cytometry to enumerate B cells and
other hematopoietic cells. In the bone marrow (BM), spleen
(SP), peripheral blood (PB), and lymph nodes (LN), Mysm1/
mice showed a drastic decrease in the percentage of
B220+CD19+ B cells, compared to WT MMTV-cre littermates
(Figure 1A). Moreover, in Mysm1/ mice, peripheral B cells
that expressed surface IgM and IgD were markedly reduced
in various tissues (Figures 1B and 1C). In contrast to the drastic
reduction in B cell frequency, the frequencies of CD3+ T and
CD4+ T lymphocytes in various tissues from Mysm1/ mice
were largely normal or increased compared to WT littermates
(Figures 1D and 1E and data not shown). Moreover, the
frequencies of other cell lineages, including Gr1+CD11b+
myeloid cells, Ter119+ erythrocytes, and CD41+Ter119 mega-
karyocytes were largely normal or elevated in various tissues of
Mysm1/ mice (data not shown). Absolute numbers of all
hematopoietic lineage cells were reduced by various degrees
(data not shown). However, the reduction in B220+CD19+ B
cell number was most dramatic in Mysm1/ mice, with only
0.25% of B cell numbers in WT mice (Figure 1F). Collectively,
these data demonstrate that MYSM1 is essential for B cell
development.(E) Percents of B220+CD19+ B cells, CD3+ T cells, CD3+CD4+, and CD3+CD8+ T c
gray column: WT) (n = 4 per group).
(F) Percentages of indicated cell numbers from BM of Mysm1/ mice compared
See also Figure S1.
IMYSM1 Is Required for Early B Cell Lineage
Commitment
Next we examined the B cell compartment of the bone marrow.
Figures 2A and 2B show that frequencies of pre-B cells (CD19+
CD25+IgMCD43) and pro-B cells (B220+CD43+CD19+c-Kit+)
were dramatically reduced in the bone marrow of Mysm1/
mice. To examine the pre-pro-B cell population, we used Ly6C
and DX5 markers to gate out natural killer (NK) cells (DX5+)
and plasmacytoid dendritic cells (pDCs) (Ly6C+) (Rumfelt
et al., 2006) in order to better identify B220+CD19CD93+
Sca1loc-KitloIL-7Ra+ pre-pro-B cells. Figure 2C shows a reduc-
tion in frequencies of the pre-pro-B cell population inMysm1/
BM. In agreement, absolute cell numbers of pro-Bandpre-Bcells
were drastically reduced (Figures 2D and 2E). Cell numbers of
pre-pro-B cells were reduced at a lesser degree. We also exam-
ined the HSC compartment of Mysm1/ and WT mice and
observed that frequencies of LinSca1+c-Kit+ (LSK) HSCs and
common lymphoid progenitors (CLPs) (LinIL-7Ra+cKit+
Sca1+)werenot apparently compromised inMysm1/mice (Fig-
ure 2F).We noticed thatmost of CLP cells in the BMofMysm1/
mice were Ly6D all-lymphoid progenitors (ALPs) with only few
Ly6D+Bcell-biased lymphoid progenitors (BLPs) (Figure 2F; Inlay
et al., 2009).We alsoexamined T cell development and found that
frequencies of both CD4+CD8+ double-positive (DP) and double-
negative (DN) T cell precursor populations were roughly compa-
rable in WT andMysm1/ thymus, although the DN1 population
frequency was increased and DN2 frequency was reduced (data
not shown). In addition,MYSM1was broadly expressed in B cells
and their precursors and other hematopoietic cells, as detected
by quantitative reverse transcriptase (qRT)-PCR (Figure S2).
Collectively, these data demonstrate a block in the early B cell
development inMysm1/ mice.
MYSM1 Has an Intrinsic Role in B Cell Development
To investigate whetherMYSM1has an intrinsic role, in vitro pre-B
cell colony-forming assays viaMethoCult M3630 (StemCell) sup-
plemented with interleukin-7 (IL-7) were performed. Figure 3A
shows that no B cell colonies were formed from Mysm1/
bone marrow cells in repeated attempts. To rule out the possi-
bility that the inability of forming pre-B cell colonies is due to
the lack of hematopoietic stem cells, we first sorted LSK cells
and then performed B cell colony-formation assays on the OP9
stromal cell culture in the presence of stem cell factor (SCF),
Fms-like tyrosine kinase-3 (Flt3), and IL-7 (Greig et al., 2010). Fig-
ure 3B also shows the inability of isolatedMysm1/ LSK cells to
form B cell colonies in repeated experiments. To confirm these
results, we further examined the propagation of sorted pro-B
cells on OP9 stromal cells in the presence of IL-7. Figure 3C
also shows that the Mysm1/ pro-B cells failed to expand in
IL-7-conditioned cultures. However, we noticed that expression
of IL-7Ra chain on CLP and pre-pro-B cells (Figures 2C and
2F), as well as on thymic DN and DP T cells (data not shown),
was not apparently perturbed inMysm1/ mice.ells in indicated tissues of WT andMysm1/mice (black column: MYSM1/;
to those from WT mice (n = 4). Error bars indicate +SD.
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Figure 2. Block in Early B Cell Development in the Absence of MYSM1
(A–C) Representative flow cytometry of the bone marrow of 6-week-old homozygous Mysm1/ mice and WT littermates (n = 3–6 per group). Numbers
adjacent indicate percentage of pre-B cells (CD19+CD25+IgMCD43) (A), pro-B cells (CD43+B220+CD19+c-Kit+) (B), and pre-pro-B cells (B220+
CD19Ly6CDX5Sca1loc-KitloIL-7Ra+CD93+) (C) in total BM nucleated cells.
(D and E) Absolute numbers (D) of indicated cells in BMofMysm1/mice andWT littermates per femur and percentages (E) ofMysm1/ cell numbers compared
to WT cell numbers (n = 3–6 per group) from one of three independent experiments.
(F) Representative flow cytometry plots of bone marrow HSC (LinSca1+c-Kit+), CLP (LinIL-7Ra+Sca1+c-Kit+), and Ly6D or Ly6D+ CLP populations of
Mysm1/ mice and WT littermates (n = 4). Numbers adjacent indicate percents of indicated subpopulations.
See also Figure S2.
Immunity
Control of B Cell Development by MYSM1To further investigate the role for MYSM1 in B cell develop-
ment, we produced a recombinant lentiviral vector (LV) that
coexpressed a full-length MYSM1 and GFP marker for rescue
assays (Figure S3). Figures 3D and 3E show that Mysm1/
BM cells transduced with LV-MYSM1 vector, but not with LV-886 Immunity 35, 883–896, December 23, 2011 ª2011 Elsevier Inc.GFP, were able to form B cell colonies in the IL-7-conditioned
culture and that differentiated cells were CD19+, indicating
that the defect in B cell differentiation of Mysm1/ BM can
be rescued by the forced expression of MYSM1. Moreover,
we performed bone marrow (BM) transplantation assays to
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Figure 3. MYSM1 Has an Intrinsic Role in B Cell Development
(A) Pre-B colony assays of bone marrow cells from Mysm1/ mice and WT littermates. B cell colony numbers (n = 3) and representative colony morphology
(bottom) on day 7 of MethoCult M3630 culture (StemCell Technologies) containing IL-7 are shown from one of three repeated experiments. *p < 0.01,Mysm1/
versus WT.
(B) B cell colony formation assays of sorted Linc-Kit+Sca1+ (LSK) hematopoietic stem cells on the OP9 stromal cell culture in the presence of SCF, Flt3, and IL-7
for 10 days. B cell colony numbers per well (n = 3) are shown from one of two repeated experiments. *p < 0.01, Mysm1/ versus WT.
(C) In vitro proliferation of sorted pro-B cells (B220+CD43+IgM) from the bonemarrow onOP9 stromal cells supplementedwith IL-7 for 5 days. B cell numbers per
well (n = 3) are shown from one of two repeated experiments.
(D and E) MYSM1 rescue assays. Bone marrow cells were transduced with a recombinant lentiviral vector LV-Mysm1 or a control LV-GFP. The transduced BM
cells were then subject to pre-B colony assays and B cell colony numbers were scored on day 7 (D). Flow cytometric analysis was performed on day 10 of the
culture (E). Data are shown from one of three repeated experiments. *p < 0.01, LV-Mysm1 versus LV-GFP.
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Immunity
Control of B Cell Development by MYSM1assess the intrinsic effects of MYSM1 in vivo. Lethally irradiated
congenic CD45.1 WT mice received a 1:1 mixture of CD45.2
bone marrow cells from Tek-cre:Mysm1 mRNA truncation-first
floxed mice or WT mice and CD45.1 WT mice. Upon analyzing
the mice at 3 weeks posttransplantation, we observed the
inability of the donor Mysm1/ BM cells to generate B220+ B
cells in the recipient mice (Figure 3F). To determine that
MYSM1 has a different role in B cell and T cell commitment
further, we then cultured LSKs from BM of WT and Mysm1/
mice with OP9 stromal cells and OP9-DL1 that express Delta-
like 1 (DL1) in the presence of cytokines Flt3L (FMS-like tyrosine
kinase 3 ligand) and IL-7 to induce T cell, as well as B cell,
differentiation in vitro (Li et al., 2010). Figure 3G shows that
T cell development of Mysm1/ LSK was largely normal
in vitro whereas B cell development was abrogated. To verify
the results of LSK culture, we also cultured CLPs sorted from
WT andMysm1/mice on either OP9 or OP9-DL1 stromal cells.
The relatively normal T cell development and inability of B cell
development of Mysm1/ CLP was also observed (Figure 3H).
Collectively, these data demonstrate that MYSM1 is critical and
intrinsic for instructing B cell but not T cell lineage commitment.
MYSM1 Derepresses Ebf1 Transcription
B cell lineage commitment and early B cell development is
governed by a small set of transcription factors (Nutt and Kee,
2007). Given that histone H2A ubiquitination is generally involved
in the repression of target gene transcription (Zhou et al., 2008;
Zhu et al., 2007), we set out to examine whether MYSM1
regulates the transcription of transcription factors that are
important for B cell lineage commitment and development. We
examined the expression of a panel of transcription factors
in CLPs and pre-pro-B cells by qRT-PCR analysis. CLPs
(LinIL-7Ra+Sca1+c-Kit+) and pre-pro-B cells (B220+CD43+
CD19CD24Ly6CDX5c-Kit+IL7-Ra+CD93+) were isolated
from BM cells by flow cytometric sorting. Figures 4A and 4B
show a drastic reduction in the mRNA of EBF1, Pax5, and other
transcription factors that are critical for B cell lineage commit-
ment and development in sorted Mysm1/ CLPs and pre-pro-
B cells. In contrast, the expression of the genes important for
T cell lineage commitment and development were normal or
elevated in Mysm1/ CLPs and thymic CD4+CD8+ DN T cells
(Figures 4A and 4C). Consistent with the observations by flow
cytometric analyses, these qRT-PCR data indicate that
MYSM1 is required for the transcription of B cell lineage-
promoting genes, such as EBF1, Pax5, and downstream genes.
Because EBF1 is a master transcription factor for B cell
lineage commitment and early development (Lin and Gros-
schedl, 1995), we investigated the association of MYSM1 with
the EBF1 locus by using chromatin immunoprecipitation
(ChIP) assays. A panel of PCR primer pairs to encompass the(F) Bone marrow transplantation. A 1:1 mixture of whole BM cells from CD45.2My
orbitally into irradiated (9.5 Gy) CD45.1 congenic mice (2 3 106 cells/mouse, n =
T cells expressing donor (CD45.2+)- or recipient (CD45.1+)-derived population w
independent experiments.
(G and H) B cell and T cell colony formation assays of HSC (LSK) (G) and CLP (H) c
cell culture in the presence of Flt3 and IL-7 for 10 days. B cell and T cell colony num
two repeated experiments. *p < 0.01, Mysm1/ versus WT OP9 culture.
See also Figure S3.
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(Lin and Grosschedl, 1995; Pongubala et al., 2008) were used
(Figure 5A). Immunoprecipitation with the MYSM1-specific
antibody, but not control IgG, enriched the sequences located
at the Ebf1a and Ebf1b promoter and enhancer regions (Fig-
ure 5B). In addition, we observed that anti-MYSM1 ChIP did
not enrich for the Ebf1 promoter sequences in thymic T cells
(Figure 5C). These data further demonstrate the direct associa-
tion of MYSM1 with the Ebf1 promoter region in B cells and their
precursors. To test whether MYSM1 is directly involved in acti-
vating Ebf1 transcription, Ebf1a and Ebf1b promoter and
enhancer region DNA fragments, as well as the promoter region
fragments of Pax5 and Cd79a, were cloned into the pGL3-Basic
Luc reporter vector (Promega), respectively (Figure S4A). Subse-
quently, we performed transcription assays by cotransfecting
one of these Luc reporter vectors and the MYSM1 expression
vector into Ba/F3 cells (Sharabi et al., 2008; Zhu et al., 2007).
MYSM1expression activated transcription of theEbf1apromoter
and modestly activated the Ebf1b promoter, but only marginally
activated the Pax5 promoter and Cd79a promoter. Moreover,
the activation of the Ebf1a and Ebf1b promoters occurred in
a dose-dependent manner (Figures S4B–S4D). To further
demonstrate the role of MYSM1-controlled EBF1 expression in
Bcell development,weperformeda rescueassaywith a retroviral
vector expressing EBF1 (MIG-Ebf1) (Greig et al., 2010). Figures
5D and 5E show thatMysm1/ BM cells transduced with MIG-
Ebf1, but not with control retroviruses, were able to form B cell
colonies and to develop into CD19+ B cells in vitro. However,
Mysm1/ BM cells transduced with MIG-Pax5 and MIG-Il7ra
were still unable to formB cell colonies. Moreover, higher endog-
enous EBF1 expression was detected inWT LinBM cells trans-
duced with the lentiviral vector expressing MYSM1 (LV-Mysm1),
compared to WT cells transduced with a control LV-GFP vector
(Figure S4E). Collectively, these data demonstrate that MYSM1
is essential for activating Ebf1 transcription, thus controlling B
cell lineage commitment and development.
MYSM1 Orchestrates Histone Modifications and
Transcription Factor Recruitment at the Ebf1 Locus
In an attempt to investigate how MYSM1 activates Ebf1 tran-
scription, we first determined whether MYSM1 deubiquitinates
ubH2A at the Ebf1 promoter locus of B cell precursors. To get
sufficient numbers of B cell precursors for ChIP assays, we iso-
lated BM lineage marker-negative (Lin) progenitors, which still
contain CLPs in Mysm1/ mice (Figure 2F). Figure 6A shows
that ubH2A was increased in the Ebf1a and Ebf1b promoter
locus of Mysm1/Lin progenitors, compared with that in WT
Lin progenitors. In contrast, there was no apparent difference
in ubH2A in EBF1 promoter desert region (PDR) and exon 2
regions, as well as in the osteocalcin (OC) promoter locus ofsm1/mice or WT littermates and CD45.1 congenic mice were injected retro-
6 per group). After 3 weeks, the relative percentages of B220+ B cells or CD3+
ere determined by flow cytometry analysis. Results are representative of two
ells sorted from BM of WT andMysm1/mice on the OP9 or OP-DL1 stromal
bers per 100 seededWT orMysm1/HSC or CLP cells are shown from one of
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Figure 4. MYSM1 Is Required for the Transcription of B Lymphoid Genes
Expression of representative transcription factors in sorted CLP (LinIL-7Ra+Sca1+c-Kit+) (A), pre-pro-B cells (B220+CD43+CD19CD24Ly6CDX5c-Kit+IL-
7Ra+CD93+) (B), and thymic CD4+ and CD8+ DN T cells (C) of WT and Mysm1/ mice detected by qRT-PCR assays. mRNA expression was normalized to
hypoxanthine-guanine phosphoribosyl transferase (Hprt) mRNA amount and presented related to their expression inWT cells, set as 1. Data are representative of
three independent experiments. Each sample was analyzed in triplicate, and error bars indicate ±SD.
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Figure 5. MYSM1 Targets the Ebf1 Locus
(A) Schematic diagram of the Ebf1 gene and its promoter and enhancer region illustrating the positions of the primers used for ChIP assays.
(B and C) ChIP assays of WT B220+ B cells via a MYSM1 antibody probing for the Ebf1 gene and regulatory sequence pull-down or IgG nonspecific pull-down
(control) (B). ChIP assays of WT B220+ B cells and WT thymocytes via the MYSM1 antibody (C). Quantitative PCR was used to analyze the enrichment. The fold
changes of enriched DNA are presented from one of three independent experiments. PDR: primers for a ‘‘promoter desert’’ region of genomic DNA upstream of
the Ebf1 promoter.
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Control of B Cell Development by MYSM1WT and Mysm1/Lin progenitors, suggesting the selective
deubiquitination of uH2A at the Ebf1 locus by MYSM1. Histone
ubiquitination and deubiquitination has been shown to coordi-
nate histone modifications and regulate gene transcription by
interacting with other histone modifiers (Campos and Reinberg,
2009). We then tested whether MYSM1 may orchestrate histone
modifications at the Ebf1 locus. Figures 6B and 6C show that
repressive trimethylated histone H3 at lysine 27 (H3K27me3) at
the Ebf1a and Ebf1b promoter locus was significantly elevated
in Mysm1/ BM Lin progenitors, whereas the permissive
trimethylated histone H3 at lysine 4 (H3K4me3) levels at the
Ebf1 promoter locus were decreased. We also tested whether
the recruitment transcriptional factors to the Ebf1 locus was
compromised due to the altered histone modifications in
Mysm1/BMprogenitors. Figure 6D shows that the recruitment
of several key transcription factors forEbf1 transcription, such as
E2A, to the Ebf1 locus was reduced in Mysm1/ BM Lin
progenitors. We also examined the binding of E2A to other target
loci (Lin et al., 2010) in Mysm1/ BM Lin progenitors. It was
observed that the binding of E2A to its target locus Dntt was
also significantly reduced in Mysm1/ cells (Figure S5).
However, to our surprise, E2A binding to other target loci,
including Pou2af1, Tcf7, and Notch1, was not reduced or even
slightly increased in Mysm1/ cells. This unexpected observa-
tion suggests a different degree of dependence on MYSM1 for
the binding of E2A to different target loci. Moreover, we observed
that recruitment of Ring1b and Bmi1, which are components of
the repressive polycomb group (PcG) complex 1 and act as an
ubiquitin E3 ligase toward histone H2A at lysine 119 (Cao
et al., 2005; de Napoles et al., 2004; Wang et al., 2004a,
2004b), to the EBF1 locus was significantly increased in
Mysm1/Lin progenitors (Figure 6D). Collectively, these data
indicate that MYSM1 not only deubiquitinates ubH2A but also
orchestrates histone modifications at the Ebf1 locus and that
its deficiency results in the repressive histone modifications
and impaired recruitment of the key transcription factors to the
Ebf1 locus.
Association with the Transcription Factor E2A and the
SWI/SNF Chromatin Remodeling Complex for EBF1
Transcription
To probe the possible interaction of endogenous MYSM1 and
the transcription factors of Ebf1, we performed coimmunopreci-
pitation assays. A weak association of endogenous MYSM1
protein and endogenous E2A (E47) protein was detected in
WT BM Lin progenitor cells, although the association of
MYSM1 and PU.1, Ikaros, Stat5, or Runx1 was not positively
identified (data not shown). To further investigate the interaction
of MYSM1 and E2A, sequential two-step ChIP assays were
performed (Zhou et al., 2008). Figure 7A shows an association
of both MYSM1 and E2A at the Ebf1 locus of WT BM Lin
progenitors. These data demonstrate an association of
MYSM1 and E2A, which may be involved in the selective target-
ing of MYSM1 to the EBF1 locus.(D–F) EBF1, Pax5, and IL-7Ra rescue assay. WT or Mysm1/Lin BM cells were
(MIG-Ebf1) (D and E), Pax5, IL-7Ra (F), or a control vector (MIG). The transduced
were examined and flow cytometric analysis performed on day 10 (E) of the cult
See also Figure S4.
ITo investigate how MYSM1 orchestrates histone modifica-
tions to regulate EBF1 transcription, we set out to identify
MYSM1-binding partners by yeast two-hybrid screens. We
used the full-length mouse MYSM1, the N-terminal region con-
taining the SANT and SWIRM domain, or the C-terminal region
containing the JAMM domain, and a generic LXXLL motif as
bait (Figure S6A). This approach of using a full-length molecule
as well as its domains as bait provides an increased specificity
and a broad spectrum of binding partner selection, based on
our previous experience (Lee et al., 2009). Several MYSM1-
binding partners that were not reported previously (Zhu et al.,
2007) were identified with a human leukocyte matchmaker
cDNA library for screening, including Brahma (BRM), also known
as SMARCA2. The SWI/SNF (Switch/sucrose non-Fermenter)
chromatin-remodeling complex contains either BRM or
Brahma-related gene 1 (BRG-1) as its central ATPase subunit
and is important for controlling gene transcription (Osipovich
et al., 2007; Reisman et al., 2009). To confirm the interaction
of MYSM1 with BRM or BRG-1, we performed coimmunopreci-
pitation assays. Figures 7B and 7C show that MYSM1 was
coprecipitated with endogenous BRM and BRG-1 in 293 cells
that were transfected with the Flag-MYSM1 expression vector
(Figure S6B). To further determine the association of MYSM1
and BRM or BRG-1 at the EBF1 promoter locus, sequential
two-step ChIP assays were performed. Figure 7D shows the
association of both MYSM1 and BRM and/or BRG-1 at the
Ebf1 promoter locus of WT BM Lin progenitors. We also exam-
ined whether BRM and BRG-1 were involved in MYSM1-medi-
ated Ebf1 transcription. Early hematopoietic progenitor cells
Ba/F3 were cotransfected with the Ebf1a promoter-Luc reporter,
siRNA, and MYSM1 expression plasmids and the transfection
of BRM siRNA or BRG-1 siRNA resulted in the reduction of
BRM or BRG-1 mRNA (Figure S6C). BRM or BRG-1 silencing
reduced MYSM1-mediated Ebf1 promoter transcription (Fig-
ure S6D). In addition, we examined the effects of BRM and
BRG1 downregulation by siRNA on the expression of the en-
dogenous Ebf1 locus. It was observed that BRM and BRG1
downregulation of WT Lin BM cells reduced endogenous
EBF1 expression (Figure S6E). Collectively, these data demon-
strate that MYSM1 interacts with E2A and BRM and/or BRG-1
and its association is probably involved in MYSM1-mediated
Ebf1 transcription in B cell precursors.
DISCUSSION
Understanding the physiological roles of histone H2A deubiqui-
tination is of fundamental importance in illustrating the epige-
netic regulation of gene transcription and cell development. So
far, the physiological roles for the entire group of histone H2A
deubiquitinases are largely unknown (Joo et al., 2007; Nakagawa
et al., 2008; Scheuermann et al., 2010; Zhao et al., 2008; Zhu
et al., 2007). Here, we have revealed that the histone H2A deubi-
quitinase MYSM1 plays an essential and intrinsic role in B cell
development by activating the pivotal target EBF1 and possiblytransduced with a recombinant retroviral vector that expresses mouse EBF1
BM cells were then subject to B cell colony formation assays. Colony numbers
ure. Data are shown from one of two independent experiments.
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Figure 6. Altered Histone Modifications and Transcription Factor Recruitment at the Ebf1 Promoter Locus in Mysm1–/– B Cell Progenitors
(A–C) ChIP analyses of WT orMysm1/BMLin cells via uH2A (A), H3K4me3 (B), H3K27me3 antibody (C), or IgG control. The precipitated DNAwas analyzed by
quantitative PCR with primers amplifying the EBF1a or EBF1b promoter regions, the EBF1 PDR region, the EBF1 exon 2 region, or the control OC promoter
region, and normalized with the input DNA before being compared to WT (set as 1). *p < 0.05, WT versus Mysm1/.
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Figure 7. MYSM1 Interacts with the Tran-
scription Factor E2A and BRM
(A) Sequential two-step ChIP assays of WT BM
Lin progenitors were performed, showing the
recruitment of the endogenous E2A and MYSM1
to the Ebf1 promoter from one of two independent
experiments. The relative binding was defined by
determining the immunoprecipitation level (ratio of
the amount of immunoprecipitated DNA to that of
the input sample) and then comparing to corre-
sponding first ChIP or second ChIP control IgG
immunoprecipitation level, which was set as 1.0.
**p < 0.01.
(B and C) Endogenous BRM and BRG1 coimmu-
noprecipitated with MYSM1. Cell lysates from
HEK293T cells transfected with a pCMV-Flag-
Mysm1 or pCMV-FLAG expression plasmid were
incubated with an anti-Flag antibody, and immu-
noprecipitated proteins were analyzed by a BRM
(B) or BRG1 (C) antibody. Ten percent of the input
was loaded.
(D) Sequential two-step ChIP assays of WT BM
Lin progenitors were performed from one of two
repeated experiments. **p < 0.01.
See also Figure S6.
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Control of B Cell Development by MYSM1other transcription factors in B cell progenitors. Further studies
revealed that MYSM1 derepresses Ebf1 transcription as a key
transcription switch by orchestrating histone modifications and
transcription factor recruitment to the locus. Thus, this study
uncovers the essential biological role of the histone H2A deubi-
quitinase MYSM1 in B cell development, as well as underscores
the biological importance of histone H2A ubiquitinases in
general.
The differentiation of lymphocytes from HSCs is controlled by
orchestrated expression of a set of shared and lineage-specific
transcription factors (Zon, 2008). Lymphopoiesis initiates with(D) ChIP analyses of the occupancy of E2A, PU.1, Bmi1, and Ring1B inWT orMysm1/BM Lin cells with a p
was analyzed by quantitative PCR via primers (primer pair A) amplifying the EBF1a promoter region for ChI
MYSM1 and via primers (primer pair E) amplifying the EBF1b promoter region for ChIP with anti-PU.1 and nor
to WT (set as 1).
*p < 0.05. See also Figure S5.
Immunity 35, 883–896, Dthe generation of CLPs, a heterogeneous
cell population with multiple differentia-
tion potential into T, B, dendritic, and NK
cells (Inlay et al., 2009), by graded expres-
sion of the transcription factors PU.1,
Ikaros, and E2A, which induce the
expression of components of signaling
pathways, including IL-7 and Flt3, for
lymphoid development (Nutt and Kee,
2007). T and B cell developmental
pathways diverge, because of their
expression of distinct lineage-specific
transcription factors (Rothenberg et al.,
2008). B cell lineage commitment from
CLPs is determined by E2A and two
lineage-specific transcription factors,
EBF1 and Pax5 (Cobaleda et al., 2007;Lin and Grosschedl, 1995), for their differentiation into pre-pro-
B and pro-B cells (Hu et al., 2006; Johnson et al., 2008; Ma
et al., 2006; Nutt and Kee, 2007). In contrast, T cell lineage differ-
entiation is driven by the expression of Notch1 and Notch-Delta
signaling in lymphoid progenitors (Rothenberg et al., 2008). We
found that MYSM1 is essential for B cell lineage, but not T cell
lineage, commitment. We identified the transcription factor
EBF1 as a pivotal target gene of MYSM1 in lymphoid precursors
and demonstrated that MYSM1 epigenetically derepresses
EBF1 transcription by orchestrating histone modifications and
regulating recruitment of the transcription factors to the EBF1anel of antibodies indicated. The precipitated DNA
P with antibodies against E2A, Bmi1, Ring1B, and
malized with the input DNA before being compared
ecember 23, 2011 ª2011 Elsevier Inc. 893
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Control of B Cell Development by MYSM1locus. EBF1 is a master transcription factor for B cell lineage
commitment and development, because its deficiency leads to
a block in early pro-B cell development (Lin and Grosschedl,
1995). EBF1 activates many genes, such as Pax5, Foxo1,
Cd79a, Cd79b, Igll1 (l5), and others, important for B cell devel-
opment (Igarashi et al., 2002; Zandi et al., 2008). Although EBF1
is expressed first in CLPs, it is not essential for early lymphoid
development, given that there are no defects in EBF1-deficient
early progenitors including the HSC, CLPs, and pre-pro-B cell
populations (Zandi et al., 2008). In this study, we demonstrated
that early B cell development was blocked at the ALP stage in
MYSM1-deficient mice, as Ly6D+ BLPs and pro-B cells were
drastically reduced. However, a considerable number of Ly6D
ALPs and pre-pro-B cells, although reduced, were still detected
in MYSM1-deficient mice. The scarcity of Ly6D+ BLP cells
suggests a developmental block at the ALP stage and/or
a speedy transition from ALP to pre-pro-B cells in Mysm1/
mice. It was recently reported that ALPs and BLPs were formed
in normal numbers in EBF1-deficient mice, whereas the defi-
ciency in IL-7 signaling blocked early B cell development at the
ALP stage (Tsapogas et al., 2011). Collectively, the data convinc-
ingly show that MYSM1 is essential for early B cell development
and that EBF1 is one important MYSM1 target gene. However,
MYSM1 probably regulates other critical target genes, upstream
of EBF1, which are responsible for the defect in the earliest stage
of B cell development in MYSM1/ mice. During the course of
this study, Oguro et al. (2010) recently reported that Bmi1, which
is associated with Ring1B and other components of Polycomb
group (PcG) complexes and is involved in H2A ubiquitination
(Cao et al., 2005; de Napoles et al., 2004; Wang et al., 2004a,
2004b), was critical not only for HSC maintenance, but also for
lymphocyte development by repressing B cell lineage develop-
mental genes, Ebf1 and Pax5 (Oguro et al., 2010). Ebf1, Pax5,
and downstream target genes were derepressed, whereas the
expression of upstream genes of Ebf1, such as Sfpi1, Tcf3,
and Il7ra, was not altered in Bmi1-deficient hematopoietic
progenitors. Bmi1 deficiency enhanced B cell lineage differenti-
ation at the expense of T cell lineage via derepressing Ebf1 and
Pax5 transcription. Taken together, the data presented in this
study demonstrate that MYSM1 plays an essential role in B
cell lineage commitment and development by epigenetically
derepressing the transcription of Ebf1 and possibly other early
lymphoid lineage developmental factors.
Transcription factors are key determinants in the complex
orchestration of hematopoiesis; however, little is known about
the underlying mechanisms by which transcription of these tran-
scription factors is regulated. Because of the highly compact
nature of genomic DNA in the chromatin of eukaryotic cells,
a transcription complex that consists of chromatin remodelers,
DNA and histone modifiers, and transcription factors need to
work in concert to reconfigure nucleosomes at specific loca-
tions, as well as to alter the promoter structure to expose regu-
latory sites for gene activation or repression (Cairns, 2009).
Despite the fact that at least five known histone H2A deubiquiti-
nases can deubiquitinate monoubiquitinated K119 H2A (Joo
et al., 2007; Nakagawa et al., 2008; Scheuermann et al., 2010;
Zhao et al., 2008; Zhu et al., 2007), MYSM1 plays a nonredun-
dant, essential biological role in B cell development. We also
found that MYSM1 not only deubiquitinated uH2A but also894 Immunity 35, 883–896, December 23, 2011 ª2011 Elsevier Inc.orchestrated histone modifications at the Ebf1 locus to activate
its transcription. These data suggest that MYSM1 interacts with
other histone modifiers to regulate chromatin status at the Ebf1
locus.
At present, a major question of how MYSM1 is targeted to the
Ebf1 gene locus remains. However, the results of this study
provide some clues. MYSM1 was found to interact with the
transcription activator E2A, as well as BRM and/or BRG-1, the
key ATPase component of the SWI/SNF chromatin-remodeling
complex (Reisman et al., 2009). Both BRM and BRG-1 are
ATPases with 80% homology in their amino acid sequence
and have shared activities, although they also have distinct
biological roles (Reisman et al., 2009). These results, together
with the data of others (Campos and Reinberg, 2009; Zhu
et al., 2007), suggest that the selective gene locus targeting
of MYSM1 may be guided by its partners such as transcription
factors and chromatin remodelers. An interesting area of
future studies is to systemically identify MYSM1 partners
and investigate the underlying molecular mechanisms for the
selective gene targeting and transcription regulation by
MYSM1. We realize that MYSM1 plays a broad role in the
hematopoietic system and regulates the transcription of Ebf1
as well as other genes. Our preliminary ChIP-seq data
identified more than 1,000 genes that are associated with
MYSM1 in B cells (unpublished data). We observed a general
reduction in absolute numbers of hematopoietic cells of all
lineages in MYSM1-deficient mice, suggesting that MYSM1
may regulate HSC, in addition to its essential role in early
B cell lineage development. Thus, further studies are war-
ranted to illustrate the biological roles and mechanisms for
the spatiotemporal control of target genes by MYSM1 in
HSCs and their progeny.
EXPERIMENTAL PROCEDURES
Mice
Mysm1 targeted vector is composed of an FRT flanked splice acceptor (En2
SA), lacZ, and neomycin and poly(A) sequence followed by a loxP site. An
additional loxP site is inserted downstream of the targeted MYSM1 exon
(E3). The Mysm1 mRNA truncation-first strategy was based on inserting
a cassette into an intron of an intact target gene that produces a truncated
mRNA at the RNA processing level. A splice acceptor (SA) in the cassette
captures the RNA transcript and an efficient polyadenylation termination
signal truncates the transcript, preventing the gene from being transcribed
into mRNA downstream of the cassette site (Figure S1A; Testa et al.,
2004). Subsequent Cre expression results in the deletion of the floxed
MYSM1 exon 3 by crossing with cre transgenic mice. The Mysm1 mRNA
truncation-first floxed sperm in the C57BL/6J background (Mysm1_A04;
Mysm1tm1a(DMP)Wtsi MGI#: 2444584) were provided by the KOMP Repository
at UC Davis. In vitro fertilization, microinjection, chimera production, and the
generation of Mysm1 mRNA truncation-first floxed mouse founders were
carried out at the USC Transgenic Mouse Core Facility. In all experiments,
WT littermates (+/+) were used for controls. Mice were maintained in a path-
ogen-free barrier facility, and all experiments were performed in accordance
with the University of Southern California Institutional Animal Care and Use
Committee.
Flow Cytometric Analyses and Cell Sorting
Sample preparation, cytometric analysis, and sorting were performed as
described previously (Sharabi et al., 2008; Song et al., 2008). Single-cell
suspensions of bone marrow (BM), thymus, lymph nodes, and spleens were
prepared and were first stained for 20min at 4Cwith CD16/CD32 Fc-blocking
antibody (2.4G2), unless indicated otherwise, in flow cytometry buffer,
Immunity
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collected on a FACSCanto II (BD) and were analyzed with FlowJo software
(TreeStar). For cell progenitor population sorting, cells from BM were first
depleted of mature hematopoietic cells with a lineage cell depletion kit
(Miltenyi Biotec) and isolated by FACSAria cell sorter.
Quantitative RT-PCR
Quantitative RT-PCR were performed as described previously (Sharabi et al.,
2008). Total RNA from isolated cells was purified with RNeasy Microkit (-
QIAGEN) according to the manufacturer’s instructions. The SuperScript III
First-Strand Synthesis kit (Invitrogen) was used for reverse transcription.
A SYBR Green PCR kit (BIO-RAD) was used for quantitative real-time PCR
and results were quantified with an ICycler IQ (BIO-RAD). Sequences of primer
pairs are in Tables S1–S3.
Lentivirus and Retrovirus Production and Transduction
Recombinant lentiviral vectors were produced and transduced as described in
our previous publications (Shen et al., 2004). Retroviruses were produced by
transient transfection of 293T cells with plasmids that encode viral proteins
(pCL-10A1) and a specific gene expression vector (pMIG-EBF1 or pMIG) as
described (Pongubala et al., 2008).
Bone Marrow Transplantation
Unfractionated BM cells (2 3 106) from WT and CD45.2-deficient mice were
transplanted into lethally irradiated (9.5 Gy) wild-type C57BL/6 (CD45.1)
mice through retro-orbital injection. PE-conjugated CD45.2 and FITC-conju-
gated CD45.1 (BD Bioscience) were used to determine the donor- or recip-
ient-derived population by flow cytometry analysis (Sharabi et al., 2008).
Peripheral blood was analyzed every week after transplantation.
Chromatin Immunoprecipitation
Chromatin was immunoprecipitated according to the manufacturer’s instruc-
tions (Cell Signaling) (Sharabi et al., 2008). In brief, single-cell suspensions
were crosslinked with 1% (vol/vol) formaldehyde. Chromatin was isolated,
digested by mung bean nuclease (MNase), sheared by sonication, and immu-
noprecipitated with antibodies. Immunoprecipitated DNA was washed and
eluted according to the manufacturer’s instructions. Eluted DNA and sheared
input material was analyzed by PCR or ligated to an adaptor and amplified by
PCR according to the manufacturer’s protocol (Illumina). For sequential-ChIP
experiments, complexes from initial anti-MYSM1 ChIP were eluted, diluted,
and then reimmunoprecipitated with Brm (610390) or BRG1 (07-478) antibody
(Zhou et al., 2008).
Yeast Two-Hybrid Screen
The Matchmaker2 Gal4 yeast two-hybrid system (Clontech, Mountain View,
CA) was used to screen for MYSM1 binding partners in the Y190 yeast
strain with MYSM1 and its domain cloned into the pGBKT7 vector in-frame
to the Gal4 binding domain and a human leukocyte matchmaker cDNA library
cloned into the pACT2 vector in-frame with the Gal4 transactivation domain
(Clontech). Library screening and recovery of plasmids was performed
according to manufacturer’s instructions and was described previously (Lee
et al., 2009).
Statistics
Groups of three to eight mice were used for statistical analysis. p values were
calculated with Student’s t test.
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